Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus MYCELEX 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus MYCELEX 7 COMBINATION PACK.
FULVICIN P/G 330 vs MYCELEX-7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
330 mg orally once daily with fatty meal to enhance absorption.
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible.
Category C
Category C
Antifungal
Antifungal